Table 7 Targeted drugs and clinical trials related to specific oncogenes and proteins
Drug | Disease | Trail name | Phase | Status | ORR/CR | NCT# | Reference |
|---|---|---|---|---|---|---|---|
MYC | |||||||
Alisertib | a selective Aurora-A inhibitor | ||||||
Alisertib, romidepsin | Relapsed or refractory NHLs | Alisertib and romidepsin in treating patients with relapsed or refractory B-cell or T-cell lymphomas | 1 | Completed | NA | NCT01897012 | – |
BCL-2 | |||||||
Navitoclax | A BCL-2, BCL-XL, and BCL-w inhibitor | ||||||
Navitoclax, rituximab | Lymphoid cancers | Safety study of navitoclax in combination with rituximab in lymphoid cancers | 1 | Active, not recruiting | – | NCT00788684 | – |
Venetoclax | A highly selective BH3 mimetic | ||||||
Venetoclax | relapsed or refractory NHLs/CLL | A phase 1 study evaluating the safety and pharmacokinetics of venetoclax in subjects with relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia | 1 | Active, not recruiting | MCL, 75%/21%; FL, 38%/14%; DLBCL, 18%/12%; MZL, 67%/0% | NCT01328626 | |
Venetoclax, bendamustine, rituximab | Relapsed or refractory FL | A study evaluating the safety and efficacy of venetoclax plus bendamustine and rituximab in comparison with bendamustine plus rituximab or venetoclax plus rituximab in participants with relapsed and refractory FL | 2 | Completed | Venetoclax, rituximab, 32.7%/13.2%; venetoclax, BR, 45.1%/27.5%; BR, 51%/23.5% | NCT02187861 | – |
Venetoclax, ibrutinib | MCL | Study of venetoclax combined with ibrutinib in subjects with mantle cell lymphoma (SYMPATICO) | 3 | Active, not recruiting | – | NCT03112174 | – |
Venetoclax, RO6870810, rituximab | Relapsed or refractory DLBCL/high-grade B-cell lymphoma | A study to evaluate safety, pharmacokinetics, and clinical activity of combination of venetoclax and RO6870810, With or without rituximab, in participants with relapsed or refractory DLBCL and high-grade B-cell lymphoma | 1 | Active, not recruiting | – | NCT03255096 | – |
Venetoclax, R-CHOP/G-CHOP | B-NHLs | A safety and pharmacokinetics study of venetoclax in participants with non-Hodgkin’s lymphoma | 1/2 | Completed | Phase 1 part: venetoclax, R-CHOP, 87.5%/79.2%; venetoclax, G-CHOP, 87.5%/78.1% | NCT02055820 | |
Venetoclax, DA-R-EPOCH | Aggressive B-NHLs | Study of venetoclax plus DA-R-EPOCH for the treatment of aggressive B-cell lymphomas | 1 | Active, not recruiting | – | NCT03036904 | – |
TP53 | |||||||
Idasanutlin | A potent and selective MDM2 antagonist | ||||||
Idasanutlin, obinutuzumab/rituximab, venetoclax | Relapsed or refractory FL/DLBCL | A study of obinutuzumab in combination with idasanutlin and venetoclax in participants with relapsed or refractory follicular lymphoma or rituximab in combination with idasanutlin and venetoclax in participants with relapsed or refractory diffuse large B-cell lymphoma | 1/2 | Active, not recruiting | – | NCT03135262 | – |
Selinexor | An inhibitor of exportin 1 | ||||||
Selinexor | Advanced hematological cancer | Safety study of the selective inhibitor of nuclear export selinexor in patients with advanced hematological cancer | 1 | Completed | 31%/6% | NCT01607892 | |
Selinexor, chemotherapy | Advanced B-NHLs | Selinexor plus chemotherapy in treating patients with advanced B-cell non-Hodgkin’s lymphoma | 1/2 | Recruiting | – | NCT03147885 | – |
ALK | |||||||
Crizotinib | The first-generation ALK tyrosine kinase inhibitor | ||||||
Crizotinib | Relapsed ALK+ lymphomas | Pilot study of crizotinib in relapsed ALK+ Lymphomas | 2 | Recruiting | – | NCT02419287 | – |
Brigatinib | The second-generation ALK tyrosine kinase inhibitor | ||||||
Brigatinib | Relapsed or refractory ALK+ ALCL | Brigatinib in relapsed or refractory ALK+ anaplastic large cell lymphoma | 2 | Recruiting | – | NCT03719898 | – |
Lorlatinib | The third-generation ALK tyrosine kinase inhibitor | ||||||
Lorlatinib | Relapsed ALK+ lymphoma | A study of oral lorlatinib in patients with relapsed ALK+ lymphoma (CRU3) | 2 | Recruiting | – | NCT03505554 | – |
